## Gene Summary
NFKBIA, standing for "NF-kappa-B inhibitor alpha," is a crucial regulatory gene within the NF-kappa-B (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling pathway. This gene encodes a member of the NF-kappa-B inhibitor family, specifically the protein I-kappa-B-alpha. It plays a vital role in modulating inflammation, immune response, and cellular proliferation and survival. NFKBIA achieves this by sequestering the NF-kappa-B transcription factor complex in the cytoplasm, thus inhibiting its ability to function. Expression of NFKBIA is widespread, reflecting its integral function in multiple cellular processes and responses to stimuli.

## Gene Drugs, Diseases, Phenotypes, and Pathways
NFKBIA is principally involved in the cellular response pathways of inflammation and immune modulation. Due to its regulatory role in NF-kappa-B signaling, it is implicated in various inflammatory conditions, autoimmune diseases, and cancers. Abnormal regulation or mutations in this gene can lead to enhanced susceptibility to certain types of infections, as well as an increased risk for inflammatory and autoimmune disorders such as rheumatoid arthritis and Crohnâ€™s disease. Additionally, as NF-kappa-B plays a crucial role in cell survival signals, dysregulation of NFKBIA's normal function can contribute to oncogenesis and the progression of certain cancers.

## Pharmacogenetics
In the context of pharmacogenetics, NFKBIA's role is significant due to its influence in modulating immune and inflammatory responses. Research has indicated variability in NFKBIA might influence the efficacy and safety profile of drugs that target NF-kappa-B pathways. These drugs are primarily used in the treatment of inflammatory diseases and certain cancers. One example is glucocorticoids, which are used extensively in inflammatory conditions; variations in NFKBIA can alter the therapeutic response to these agents. Moreover, NFKBIA polymorphisms might also influence responses to chemotherapy in cancer therapies, particularly in how cancer cells evade apoptosis. Therefore, studying individual variations in the NFKBIA gene can provide insights into personalized drug therapy effectiveness and safety, particularly in treatments involving inflammation and immune modulation.